|Table of Contents|

Synthesis and Identification of Imidafenacin

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2013年04期
Page:
96-
Research Field:
生命科学
Publishing date:

Info

Title:
Synthesis and Identification of Imidafenacin
Author(s):
Zhao Yanan; Zhang Hao; Sheng Yue; Li Gang
Testing and Analysis Center,Nanjing Normal University,Nanjing 210023,China
Keywords:
anticholinergic drug; the new synthesis of Imidafenacin; modern instrument analysis; structure determination and analysis
PACS:
O723
DOI:
-
Abstract:
To establish a method for the determination of the chemical structure of Imidafenacin,the experiment was designed to synthesize Imidafenacin.Elemental analysis(EA),Thermal analysis(TA),Fourier transform infrared spectroscopy(FT-IR),Ultraviolet spectrum(UV),Nuclearmagnetic resonance(NMR),and the X-ray powder diffraction(XRD)were adopted to analyze the chemical structure of Imidafenacin.The result showed that the structure of Imidafenacin is 4-(2-methyl-1H-imidazole-1-base)-2,2-diphenylbutylamide.The design of synthetic route is reasonable.The result of the method is accurate.

References:

[1] Yamada S Z,Seki M,Ogoda M.Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent,imidafenacin,to treat overactive bladder[J].Journal of Pharmacology and Experimental Therapeutics,2011,336(2):365-371.
[2]Ohno T,Nakayama K,Nakade S.Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects[J].Journal of Clinical Pharmacology,2008,48(3):330-334.
[3]Ohno T,Nakade S,Nakayama K.Absolute bioavailability of imidafenacin after oral administration to healthy subjects[J].British Journal of Clinical Pharmacology,2008,65(2):197-202.
[4]Nakade S,Ohno T,Nakayama K.No effect of imidafenacin,a novel antimuscarinic drug,on digoxin pharmacokinetics in healthy subjects[J].Drug Metabolism and Pharmacokinetics,2008,23(2):95-100.
[5]Ohmori S,Miura M,Toriumi C.Absorption,metabolism,and excretion of [C-14]imidafenacin,a new compound for treatment of overactive bladder,after oral administration to healthy male subjects[J].Drug Metabolism and Disposition,2007,35(9):1 624.
[6]周定安,王砺,陈双峰.膀胱过度活动症的研究概况[J].现代生物医学进展,2010,12(10):4 163.
[7]郭辉,张玉泉.膀胱过度活动症新药——咪达那新[J].齐鲁药事,2008,27(5):317.
[8]李钢,金同顺,尤娟,等.生、煅磁石的分析与比较[J].应用化学,2005,22(11):1 230.
[9]马超,黄长高,陈小青,等.唑尼沙胺化学结构分析[J].药物分析杂志,2009,29(10):1 607.
[10]李钢,苏国强,徐群为,等.那格列奈的新晶型[J].药学学报,2001,37(7):532.
[11]Hiroyuki,Miyachi,Kazo,et al.Imidazole derivatives and process for preparing the same:US,5932607A[P].1999-08-03.
[12]郭炜,程进荣,王长生.4-(2-甲基-1-咪唑基)-2,2-二苯基丁酰胺的制备方法:中国,101362721A[P].2009-02-11.
[13]Ishiguro,Yuuji,Aizawa,et al.Process for producing muscarine receptor antagonist intermediate therefor:WO,2006064945A1[P].2006-06-22.

Memo

Memo:
-
Last Update: 2013-12-30